{
  "id": 1982424,
  "title": "BioMarin is acquiring Alesta Therapeutics for $275 million to develop a first oral rare bone disease treatment",
  "url": "https://urgent.news/2026/08/19/biomarin-is-acquiring-alesta-therapeutics-for-275-million-to-develop",
  "topic": "business",
  "section": "Business",
  "published": "2026-08-19T17:30:29.000Z",
  "source": {
    "name": "Quartz",
    "slug": "quartz",
    "url": "https://qz.com/biomarin-acquiring-alesta-therapeutics-rare-bone-disease-081926"
  },
  "original_language": "en",
  "account": null,
  "summary": "The deal gives BioMarin access to ALE1, a small-molecule drug in early-stage trials that could become the first oral therapy for hypophosphatasia",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}